CelLBxHealth (FRA:DWV) Total Equity: €8.23 Mil (As of Dec. 2025)


What is CelLBxHealth Total Equity?

CelLBxHealth FRA:DWV Total Equity is €8.23 Mil as of Dec. 2025. The stock has 5 warning signs investors should review.

CelLBxHealth's total equity for the quarter that ended in Dec. 2025 was €8.23 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

CelLBxHealth Total Equity Historical Data

* Premium members only.

The historical data trend for CelLBxHealth's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CelLBxHealth Total Equity Chart

CelLBxHealth Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 47.46 46.07 26.63 22.26 8.23

CelLBxHealth Semi-Annual Data
Apr16 Oct16 Apr17 Oct17 Apr18 Oct18 Apr19 Oct19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.63 28.96 22.26 13.76 8.23

CelLBxHealth Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

CelLBxHealth's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=14.387-6.16
=8.23

CelLBxHealth's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=14.387-6.16
=8.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €8.23 Mil mean?
CelLBxHealth (FRA:DWV) has a Total Equity of €8.23 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for CelLBxHealth and its competitors.
Is CelLBxHealth's Total Equity too high?
CelLBxHealth's current Total Equity is €8.23 Mil.
How does CelLBxHealth's Total Equity compare to TMO and DHR?
CelLBxHealth's Total Equity of €8.23 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Medical Diagnostics & Research company?
A good Total Equity depends on the Medical Diagnostics & Research industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for CelLBxHealth and its competitors. CelLBxHealth's current Total Equity is €8.23 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CelLBxHealth stock overvalued right now?
Based on GuruFocus' analysis, CelLBxHealth (FRA:DWV) is currently considered Possible Value Trap. The stock's GF Value™ is €0.07, compared to a current price of €0.02 — trading 75.7% below its estimated fair value. The current Total Equity is €8.23 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For CelLBxHealth (FRA:DWV), the current Total Equity is €8.23 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CelLBxHealth Business Description

Other Exchanges ANPCF:USACLBX:UK
Address 10 Nugent Road, The Surrey Research Park, Surrey, Guildford, GBR, GU2 7AF
CelLBxHealth PLC is active in the healthcare sector in the United Kingdom. The Company's principal trading activity is undertaken in relation to the development and commercialization of the Parsortix cell separation system, with deployment in liquid biopsy that is non-invasive cancer diagnostics. It is a medical diagnostic company specializing in the development of pioneering products in cancer diagnostics. Its patented Parsortix technology can potentially treat and diagnose various forms of cancer. The Parsortix system can capture and harvest CTCs from patient blood. Its geographical segments include Europe and North America, of which the majority of its revenue is generated from Europe.